Cargando…
Antibody Therapy of Pediatric B-Cell Lymphoma
B-cell lymphoma in children accounts for about 10% of all pediatric malignancies. Chemotherapy has been very successful leading to an over-all 5-year survival between 80 and 90% depending on lymphoma type and extent of disease. Therapeutic toxicity remains high calling for better targeted and thus l...
Autores principales: | Meyer-Wentrup, Friederike, de Zwart, Verena, Bierings, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613754/ https://www.ncbi.nlm.nih.gov/pubmed/23565504 http://dx.doi.org/10.3389/fonc.2013.00068 |
Ejemplares similares
-
Upcoming immunotherapeutic combinations for B-cell lymphoma
por: Greve, Patrick, et al.
Publicado: (2021) -
The Prognostic Value of Eight Immunohistochemical Markers Expressed in the Tumor Microenvironment and on Hodgkin Reed-Sternberg Cells in Pediatric Patients With Classical Hodgkin Lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2022) -
Antibody Therapy for Pediatric Leukemia
por: Vedi, Aditi, et al.
Publicado: (2014) -
Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma
por: Greve, Patrick, et al.
Publicado: (2023) -
Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2020)